These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27103068)

  • 1. Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules.
    Robertson DS; Prevost AT; Bowden J
    Stat Med; 2016 Sep; 35(22):3907-22. PubMed ID: 27103068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility.
    Kimani PK; Todd S; Stallard N
    Stat Med; 2013 Jul; 32(17):2893-910. PubMed ID: 23413228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the data combination rule for seamless phase II/III clinical trials.
    Hampson LV; Jennison C
    Stat Med; 2015 Jan; 34(1):39-58. PubMed ID: 25315892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjusting for treatment selection in phase II/III clinical trials with time to event data.
    Khan JN; Kimani PK; Glimm E; Stallard N
    Stat Med; 2023 Jan; 42(2):146-163. PubMed ID: 36419206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
    Bretz F; Schmidli H; König F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):623-34. PubMed ID: 16972714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of methods for constructing confidence intervals after phase II/III clinical trials.
    Kimani PK; Todd S; Stallard N
    Biom J; 2014 Jan; 56(1):107-28. PubMed ID: 24173686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: opportunities and limitations.
    Jenniso C; Turnbull BW
    Biom J; 2006 Aug; 48(4):650-5; discussion 660-2. PubMed ID: 16972717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation after subpopulation selection in adaptive seamless trials.
    Kimani PK; Todd S; Stallard N
    Stat Med; 2015 Aug; 34(18):2581-601. PubMed ID: 25903293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations.
    Schmidli H; Bretz F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):635-43. PubMed ID: 16972715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How practical are adaptive designs likely to be for confirmatory trials?
    Gould AL
    Biom J; 2006 Aug; 48(4):644-9; discussion 660-2. PubMed ID: 16972716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response adaptive randomization procedures in seamless phase II/III clinical trials.
    Zhu H; Piao J; Lee JJ; Hu F; Zhang L
    J Biopharm Stat; 2020; 30(1):3-17. PubMed ID: 31454295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection.
    Carreras M; Brannath W
    Stat Med; 2013 May; 32(10):1677-90. PubMed ID: 22744936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive seamless designs with interim treatment selection: a case study in oncology.
    Carreras M; Gutjahr G; Brannath W
    Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plan to be flexible: a commentary on adaptive designs.
    Shih WJ
    Biom J; 2006 Aug; 48(4):656-9; discussion 660-2. PubMed ID: 16972718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seamless phase II/III designs.
    Stallard N; Todd S
    Stat Methods Med Res; 2011 Dec; 20(6):623-34. PubMed ID: 20724313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A varying-stage adaptive phase II/III clinical trial design.
    Dong G
    Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interval and point estimation in adaptive Phase II trials with binary endpoint.
    Nhacolo A; Brannath W
    Stat Methods Med Res; 2019 Sep; 28(9):2635-2648. PubMed ID: 29921157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.
    Bratton DJ; Phillips PP; Parmar MK
    BMC Med Res Methodol; 2013 Nov; 13():139. PubMed ID: 24229079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.